Day: May 9, 2025

Reports first quarter 2025 total revenue of $7.2 million, representing 28% growth compared to the first quarter of 2024.Reports record quarterly service revenue led by strong validation activity.Reports first quarter gross margin of 6%, representing a 33-percentage point improvement compared to the first quarter of 2024. Announced a global Distribution and Collaboration Agreement with the Life Science business of Merck KGaA, Darmstadt, Germany, which operates in the U.S. as MilliporeSigma (“MilliporeSigma”). Reaffirms full-year 2025 total revenue guidance of at least $32.0 million.LEXINGTON, Mass., May 09, 2025 (GLOBE NEWSWIRE) — Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing...

All amounts in U.S. dollars unless otherwise stated TORONTO, May 09, 2025 (GLOBE NEWSWIRE) — Onex Corporation (TSX: ONEX) today announced its financial results for the first quarter ended March 31, 2025. “Onex continues to make progress and is benefitting from recent operational enhancements and a focus on areas where we have a proven right to compete,” said Bobby Le Blanc, CEO and President. “Our Private Equity and Credit teams have raised an aggregate of $2.5 billion in fee-generating capital since the start of the year, and our teams continue to advance their near- and long-term value creation plans. Our debt-free balance sheet includes $1.6 billion of liquidity, providing additional security and flexibility, including for ongoing share repurchases.”Financial Results($ millions except per share amounts) Quarter Ended March...

Initial proof-of-concept data from the ongoing BBI-355 Phase 1/2 POTENTIATE trial in patients with oncogene-amplified cancers anticipated in the second half of 2025 Novel Kinesin program on track for mid-2025 development candidate nomination and IND filing in the first half of 2026 $138 million cash position provides operating runway into 2027 SAN DIEGO, May 09, 2025 (GLOBE NEWSWIRE) — Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced financial results and business highlights for the fiscal quarter ended March 31, 2025. “Boundless remains committed to delivering new therapeutic options to patients with high unmet need oncogene amplified cancers,”...

Completed KT-621 (STAT6) SAD/MAD Phase 1 healthy volunteer trial with data to be reported in June 2025 First patient dosed in KT-621 (STAT6) BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD) with data expected in 4Q25 KT-579 (IRF5) new oral immunology degrader program, with broad clinical potential in rheumatic and other autoimmune diseases, expected to enter Phase 1 clinical trial in early 2026 KT-474/SAR444656 (IRAK4) Phase 2b trials in HS and AD ongoing, led by partner Sanofi; Kymera achieved a $20 million milestone payment as part of the IRAK4 collaboration in April 2025 Strategic decision made not to advance KT-295 (TYK2) into further clinical development to focus our team and incremental financial resources on the rapidly progressing STAT6 program Well-capitalized with $775 million in cash as of March 31, 2025,...

Management to host investor conference call today, May 9th, at 8:30am ET MIAMI, May 09, 2025 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced financial and operating results for the first quarter ended March 31, 2025. Business Highlights:Continued engagement with the U.S. Food and Drug Administration (FDA) on the Premarket Approval (PMA) application for the CGuard Prime carotid stent system in the U.S. Optimistic for an anticipated approval in the third quarter of 2025 Advanced commercial infrastructure and operational readiness ahead of anticipated U.S. launch Continued enrollment with excellent pace in the CGUARDIANS II pivotal study of the CGuard Prime carotid stent system for use...

– Q1 revenue of $24.5 million increased 1.9% year-over-year, in line with expectations for Vireo’s established markets – – Merger Transactions expected to begin closing in Q2 and further strengthen profitability profile – MINNEAPOLIS, May 09, 2025 (GLOBE NEWSWIRE) — Vireo Growth Inc. (“Vireo” or the “Company”) (CSE: VREO; OTCQX: VREOF), today reported financial results for its first fiscal quarter ended March 31, 2025. Key financial results are presented below in summary form with supporting commentary and discussion from management of certain key operating metrics which the Company uses to judge its performance. All currency figures referenced herein are denominated in U.S. dollars.  Summary of Key Financial Metrics                           Three Months Ended    US $ in millions March 31,      2025     2024     Variance                   GAAP...

MONTREAL, May 09, 2025 (GLOBE NEWSWIRE) — Aya Gold & Silver Inc. (TSX: AYA; OTCQX: AYASF) (“Aya” or the “Corporation”) is pleased to report continued operational progress at its Zgounder Silver Mine, driven by a strong mine ramp up, exceptional mill performance, a clear path to improve recovery, and solid April production. April Production MetricsProduction Metrics   Q1-2024 Q1-2025 April 2025Silver production oz 366,362 1,068,652 345,550Tonnage processed kt 81,331 249,743 90,763Silver recovery % 82 82 80Mill availability % 96 91 98Mine production t 106,880 194,661 82,496Operational HighlightsMine ramp-up continues to exceed expectations, with 2,750 tonnes per day (“tpd”) mined in April 2025. Mill throughput and availability in April are above expectations, averaging 3,025 tpd at 98% availability.Recovery...